Kerry D. Ingalls - Mar 16, 2022 Form 4 Insider Report for Poseida Therapeutics, Inc. (PSTX)

Role: Chief Operating Officer
Signature: /s/ Harry J. Leonhardt, Attorney-in-Fact
Stock symbol: PSTX
Transactions as of: Mar 16, 2022
Transactions value $: $11,940
Form type: 4
Date filed: 3/18/2022, 08:01 PM
Previous filing: Mar 1, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PSTX	Common Stock	Purchase	$11.9K	+3K	+5.77%	$3.98	55K	Mar 16, 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.965 to $3.98 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.965 to $3.98 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.